Menu
Annual · values2025202420232022202120202019
Operating Cash Flow-57.57 M USD7.46 M USD126.22 M USD535.98 M USD368.57 M USD152.19 M USD24.11 M USD
Depreciation & Amortization23.56 M USD20.85 M USD12.90 M USD7.57 M USD6.41 M USD5.59 M USD3.81 M USD
Stock-Based Compensation30.17 M USD49.41 M USD34.59 M USD18.67 M USD10.46 M USD24.63 M USD1.68 M USD
Capital Expenditures13.15 M USD29.66 M USD65.55 M USD17.09 M USD14.85 M USD25.41 M USD17.15 M USD
Cash Flow from Investing-31.41 M USD-24.32 M USD-122.31 M USD-267.61 M USD105.66 M USD6.07 M USD-17.15 M USD
Cash Flow from Financing-16.50 M USD-235.71 M USD-61.09 M USD-187.50 M USD-159.05 M USD53.21 M USD-4.17 M USD
Dividends Paid
Stock Buybacks0 USD0 USD33.66 M USD0 USD
Free Cash Flow-70.72 M USD-22.19 M USD60.67 M USD518.89 M USD353.72 M USD126.78 M USD6.97 M USD

Maravai Lifesciences Holdings Inc. is a notable entity within the biotechnology and life sciences sector, primarily focused on providing critical products and services that advance scientific research and development. The company's main are the production of nucleic acids and biologics, which are essential components in fields such as drug development, diagnostics, and molecular testing. Maravai is deeply involved in supplying innovative solutions for the synthesis and modification of nucleic acids, enabling breakthroughs in messenger RNA (mRNA) technology, a key area in the development of vaccines and therapies. The company's operations are integral to various industries where precision and cutting-edge biological research are paramount. Its contributions have been particularly impactful in accelerating the development of vaccines and treatments in response to the global demand for advanced biopharmaceutical solutions. With a strong commitment to supporting scientific innovation, Maravai Lifesciences Holdings Inc. holds a significant role in the life sciences market, providing foundational tools that empower researchers and healthcare institutions worldwide to achieve advancements in health and medicine.